Are you searching for Neo-Epitopes?
Our unique NeoScreen™ Assay allows you to identify top neo-epitope candidates.
Immune recognition starts with MHC I and MHC II.
Learn why you can rely on Immunitrack’s competence in manufacturing immune reagents.
Our aim is to help our customers predict the immune response. Immunogenicity prediction is a key need in the feld of biologics, particularly for cancer vaccines. We want to help our customers to identify “real” epitopes (those that will cause a T-cell response) from pools of potential neo-epitopes generated by sequencing data.
Conversely (e.g., protein/peptide-based therapeutics), there is often a need to predict if an unwanted immune response can occur.
Watch videoWhen you’re investigating the immune response, you need reagents you can rely on.
Immunitrack has an extensive list of the most common MHC/epitope reagents both monomers and tetramers, as well as FcRn. Click on the category of interest to find out more.
Immunitrack proposes also the production of customized MHC I & II reagents as well as MHC binding assays on request. Contact us on info@immunitrack.com to discuss projects.
Reduce the immunogenicity of therapeutic proteins. Maintain function and develop best-in-class biologics.
